ArticleCell communication and signaling : CCS2026
Defective HLA-G1 glycosylation disrupts Siglec-7-mediated NK cell tolerance at the maternal-fetal interface in recurrent pregnancy loss.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunoglobulins in recurrent pregnancy loss: Emerging biomarkers and therapeutic targets.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRecurrent pregnancy loss (RPL) remains largely unexplained in a significant subset of patients, where defective immune regulation at the maternal–fetal interface is suspected. Extravillous trophoblasts (EVT) express HLA-G1, a nonclassical MHC-I molecule crucial for immune tolerance. However, the role of HLA-G1 glycosylation in modulating the decidual natural killer (dNK) cell response remains poorly understood.
methodsWe analysed transcriptomic data and placental tissues from RPL and normal pregnancy to assess glycosylation-related alterations. Biochemical enrichment, lectin binding, and flow cytometry were used to characterize HLA-G1 sialylation. Co-immunoprecipitation and site-directed mutagenesis were used to evaluate the interaction between HLA-G1 and Siglec-7. Functional assays with JAR and NK-92MI cells were used to assess the impact on EVT invasion and NK cytotoxicity.
resultsWe identified Asn110-linked sialylation as a critical posttranslational modification of HLA-G1 that enables binding to Siglec-7, an inhibitory receptor highly expressed on dNK cells. This interaction is lost upon neuraminidase treatment or Asn110 mutation, which also impairs HLA-G1 surface localization and promotes lysosomal degradation. Functionally, disruption of HLA-G1 sialylation enhances NK cytotoxicity and cytokine release while reducing EVT invasiveness.
conclusionsOur study defines a novel glycoimmune checkpoint at the maternal–fetal interface, where Asn110-dependent HLA-G1 sialylation restrains NK cell activity via Siglec-7. This mechanism, which is disrupted in RPL, expands the physiological relevance of the Siglec axis from cancer to reproductive tolerance and highlights glycosylation as a potential target for immune modulation in pregnancy complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.